3-24-2016

Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk

Weifei Zhu  
*Cleveland Clinic*

Jill C. Gregory  
*Cleveland Clinic*

Elin Org  
*University of California*

Jennifer A. Buffa  
*Cleveland Clinic*

Nilaksh Gupta  
*Cleveland Clinic*

*See next page for additional authors*

Follow this and additional works at: https://engagedscholarship.csuohio.edu/scimath_facpub

Part of the Mathematics Commons

How does access to this work benefit you? Let us know!

Repository Citation

Zhu, Weifei; Gregory, Jill C.; Org, Elin; Buffa, Jennifer A.; Gupta, Nilaksh; Wang, Zeneng; Li, Lin; Fu, Xiaoming; Wu, Yuping; Mehrabian, Margaret; Sartor, R. Balfour; McIntyre, Thomas M.; Silverstein, Roy L.; Tang, W.H. Wilson; DiDonato, Joseph A.; Brown, J. Mark; Lusis, Aldons J.; and Hazen, Stanley L., "Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk" (2016). Mathematics Faculty Publications. 197.  
https://engagedscholarship.csuohio.edu/scimath_facpub/197

This Article is brought to you for free and open access by the Mathematics Department at EngagedScholarship@CSU. It has been accepted for inclusion in Mathematics Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk


SUMMARY

Normal platelet function is critical to blood homeostasis and maintenance of a closed circulatory system. Heightened platelet reactivity, however, is associated with cardiometabolic diseases and enhanced potential for thrombotic events. We now show gut microbes, through generation of trimethylamine N-oxide (TMAO), directly contribute to platelet hyperreactivity and enhanced thrombosis potential. Plasma TMAO levels in subjects (n > 4,000) independently predicted incident (3 years) thrombosis (heart attack, stroke) risk. Direct exposure of platelets to TMAO enhanced sub-maximal stimulus-dependent platelet activation from multiple agonists through augmented Ca\(^{2+}\) release from intracellular stores. Animal model studies employing dietary choline or TMAO, germ-free mice, and microbial transplantation collectively confirm a role for gut microbiota and TMAO in modulating platelet hyperresponsiveness and thrombosis potential and identify microbial taxa associated with plasma TMAO and thrombosis potential. Collectively, the present results reveal a previously unrecognized mechanistic link between specific dietary nutrients, gut microbes, platelet function, and thrombosis risk.

INTRODUCTION

Cardiovascular arterial thrombotic events, such as myocardial infarction and stroke, are a leading cause of disability and mortality. Platelet activation, aggregation, and the subsequent generation of an occlusive intra-arterial thrombus are essential steps in atherothrombotic disease, and enhanced platelet reactivity is associated with both the extent of end organ injury and adverse prognosis (Frossard et al., 2004; Tantry et al., 2013). Platelet hyperreactivity and thrombosis risk are enhanced in the setting of numerous conditions associated with atherosclerotic heart disease, such as hyperlipidemia, oxidant stress, and hyperglycemia (Podrez et al., 2007; Chen et al., 2008; Zhu et al., 2012). Understanding the mechanisms through which platelets become hyperresponsive and more prone to clot formation is therefore of considerable importance (Jennings, 2009).

The past decade has witnessed a rapidly growing awareness of the involvement of gut microbial organisms in the development of numerous cardiometabolic phenotypes (Bäckhed et al., 2004; Turnbaugh et al., 2006; Cox et al., 2014). For example, recent studies reveal participation of gut microbes in a metaorganismal pathway that contributes to the development of atherosclerosis (Wang et al., 2011; Koeth et al., 2013; Tang et al., 2013; Gregory et al., 2015). Briefly, specific trimethylamine (TMA)-containing dietary nutrients, such as phosphatidylcholine, choline, and carnitine, can be used by gut microbes as a carbon fuel source. A waste product produced is TMA, which is carried via the portal circulation to the liver, where it is rapidly converted by a family of enzymes, host hepatic flavin monooxygenases (FMOs), into TMA N-oxide (TMAO) (Wang et al., 2011). Animal model studies show direct provision of TMAO within the diet is pro-atherogenic, and similarly, provision of its dietary precursors (e.g., choline, carnitine, gamma butyrobetaine) also accelerates atherosclerosis development, but only in the setting of intact gut microbiota and TMA/TMAO generation (Wang et al., 2011; Koeth et al., 2013, 2014). Recent studies involving genetic manipulation of FMO3, the major FMO responsible for converting TMA into TMAO (Bennett et al., 2013), further confirm the involvement of this metaorganismal pathway in both atherosclerosis development and regulation of whole-body cholesterol and sterol metabolism (Miao et al., 2015; Shih et al., 2015; Warrier et al., 2015). Moreover, an obligatory role for gut microbes in TMAO generation in humans was affirmed by two distinct studies involving ingestion of either isotope-labeled phosphatidylcholine or isotope-labeled carnitine as a tracer before versus following exposure to an oral cocktail of poorly absorbed antibiotics to suppress intestinal microbes (Tang et al., 2013; Koeth et al., 2013). Finally, an association between plasma TMAO levels and both the extent of coronary...
atherosclerotic plaque burden and CVD risks has been observed in multiple distinct clinical studies (Wang et al., 2011; Tang et al., 2013, 2014, 2015; Lever et al., 2014).

Insights into the mechanisms through which the meta-organismal pathway responsible for TMAO production are associated with enhanced CVD risks have thus far focused on the involvement of TMAO and FMO3 in atherosclerotic plaque development, altered sterol and glucose metabolism, and changes in macrophage phenotype (Wang et al., 2011; Koeth et al., 2013; Miao et al., 2015; Shih et al., 2015; Warrier et al., 2015). The involvement of gut microbes and TMAO in modulation of platelet function and thrombosis risks in vivo has not yet been reported.

RESULTS

Plasma TMAO Levels Predict Incident Thrombotic Event Risk

We previously reported an association between plasma levels of TMAO and incident risk for the composite of major adverse cardiovascular events in a cohort of sequential stable subjects (n = 4,007) presenting to a cardiology clinic for elective diagnostic cardiac evaluations and for whom adjudicated longitudinal follow-up (3 year) for incident development of myocardial infarction (MI), stroke, death, or need for revascularization were collected (Tang et al., 2013). Initially, we therefore sought to reanalyze the clinical dataset and test whether an association between plasma levels of TMAO and incident risk for thrombotic events (MI or stroke) was observed.

Plasma TMAO levels within the cohort showed a large dynamic range (0.06 to 312 μM; Figure 1A). TMAO showed a dose-dependent association with increased cumulative burden of incident thrombotic events as illustrated by Kaplan-Meier survival analyses (Figure 1A). Importantly, the association between TMAO and incident thrombosis risk was observed even following adjustments for CVD history, traditional CVD risk factors, renal function, and medication use (fourth quartile level versus first quartile, adjusted 1.64-fold risk, p < 0.001; Figure 1A).
TMAO Directly Enhances Human Platelet Responsiveness to Multiple Agonists

The robust association observed between increasing TMAO levels and incident risk of thrombotic events in subjects served as impetus for further studies aimed at testing the hypothesis that TMAO may directly modulate platelet function. Initially, platelet-rich plasma was isolated from healthy volunteers with low levels of TMAO (all in first quartile, < 2.4 μM), and the effect of physiologically relevant levels of exogenous TMAO (100 μM versus vehicle) on platelet activation by the agonist ADP, as monitored by platelet aggregometry, was examined. While inter-individual variations in the magnitude of the effect of TMAO on platelet responsiveness to ADP stimulation was seen (Figure S1), overall, a leftward shift (p < 0.0001) in the dose-response curve in the presence of high TMAO levels was observed (Figure 1B, left). Upon further examination, the enhancing effect of TMAO on platelet function was seen to be more generalizable, since similar results were observed using washed human platelets briefly incubated in the presence versus absence of TMAO (100 μM) and varying doses of thrombin instead of ADP as agonist (Figure 1B, right).

Next, we examined the effect of TMAO on platelet adhesion to collagen, a highly thrombogenic component of the sub-endothelium (Furie and Furie, 2008). Platelets within whole blood were fluorescently labeled, and adherence to the collagen surface of a microfluidic device under physiological shear forces was monitored in real time by microscopy, as described in the Experimental Procedures. Figure 1C shows representative images of the collagen-coated biochip under flow with whole blood from a typical subject at initial (t = 0) and subsequent 1-min interval periods of exposure and illustrates the visible increase in fluorescent platelet adhesion noted in the presence of TMAO. Computer image-assisted quantification of adherent platelets was employed, and cumulative data from multiple subjects (n = 11) are shown in Figure 1D. TMAO significantly (p < 0.0001) increased platelet adhesion within whole blood to immobilized collagen under physiological shear force. In the absence of collagen coating (± TMAO), platelet adhesion to the biochip surface was negligible (Figure 1D). Cumulatively, the above data demonstrate that physiological levels of TMAO directly enhance platelet responsiveness to multiple distinct agonists (ADP, thrombin, and collagen).

TMAO Enhances In Vivo Thrombosis

Since the enhancing effect of TMAO on platelet responsiveness is both rapid and direct, we reasoned that we should be able to induce a relatively acute rise in plasma TMAO levels within the physiologically observed range and simultaneously enhance in vivo thrombosis potential. To test this, plasma TMAO levels in mice were raised using intraperitoneal (i.p.) TMAO injection (versus normal saline), and we quantified in vivo thrombosis potential using a carotid artery injury (FeCl₃) model using fluorescently tagged platelets and intravital microscopy (we aimed to perform the thrombosis model when plasma TMAO was ~100 μM, as described in the Experimental Procedures). Figure 1E shows representative images of thrombus development within the internal carotid artery at various time points following FeCl₃ injury in a representative mouse injected with either TMAO or vehicle (normal saline). At the time of the carotid artery injury (2 hr following TMAO i.p. injection), a >10-fold increase in plasma TMAO was observed that is well within the (patho)physiological range observed in humans (Figure 1E; 93.0 ± 12.5 μM versus 7.2 ± 0.5 μM TMAO in TMAO versus vehicle, respectively; p < 0.001; n ≥ 5 per group). As can be seen in Figure 1E, the rate of fluorescent thrombus formation is increased by TMAO. Further, the occlusion time, monitored by direct visualization of when platelets cease to pass downstream of the growing thrombus, is significantly (p < 0.001) shorter in TMAO-injected mice (Figure 1F).

TMAO Promotes Platelet Hyperresponsiveness by Enhancing Stimulus-Dependent Release of Ca²⁺ from Intracellular Ca²⁺ Stores

Under resting conditions, platelets maintain a low intracellular cytosolic calcium ([Ca²⁺]) level as they circulate through healthy vessels. However, at sites of vessel injury, platelets are rapidly activated by stimulus-dependent mobilization of [Ca²⁺], a precursor to thrombus formation and hemostasis (Rink and Sage, 1990; Furie and Furie, 2008). To explore how TMAO influences platelet [Ca²⁺], washed platelets from healthy donors were loaded with Fura 2-AM, a calcium-selective dye, to permit real-time monitoring of [Ca²⁺] in Fura 2-AM loaded platelets incubated with sub-maximal thrombin-evoked augmentation of platelet [Ca²⁺], in a dose-dependent manner (Figures 2A and 2B). In parallel studies TMAO similarly increased a sub-maximal ADP-triggered (1 μM) rise in platelet [Ca²⁺] (Figures S2A and S2B). The stimulatory effect of TMAO on platelet responsiveness to agonist was observed to occur rapidly, since only brief exposure (10 min) to TMAO significantly enhanced stimulus triggered rise in [Ca²⁺], (data not shown) and platelet aggregation (Figure S2C). To determine whether TMAO affects the release of Ca²⁺ from platelet stores or the entry of Ca²⁺ from extracellular media, we first examined [Ca²⁺] in Fura 2-AM loaded platelets incubated with sub-maximal thrombin dose in media in the absence of free Ca²⁺ (and 0.1 mM EGTA was added to the medium) in the presence versus absence of TMAO. As seen in Figure 2C (left), under these conditions, platelet activation in the presence of TMAO resulted in an initial several-fold enhancement in the rise of [Ca²⁺], indicating an intracellular source of Ca²⁺ is sufficient for TMAO-induced augmentation in the stimulus-dependent rise in [Ca²⁺]. With sustained incubation in media containing excess Ca²⁺ chelator, platelet [Ca²⁺], eventually plunges, consistent with depletion of intracellular stores triggering plasma membrane Ca²⁺ channel opening. Subsequent addition of excess Ca²⁺ to the external media reveals a sustained increase in [Ca²⁺], but no significant effect of TMAO on Ca²⁺ entry rate from the extracellular pool (Figures 2C and 2D). Finally, TMAO was seen to augment inositol-1,4,5-trisphosphate (IP₃) signaling pathways in platelets with either sub-maximal thrombin (Figure 2E) or ADP (Figure 2F) as agonists by quantifying inositol phosphate levels.
Dietary Choline Enhances Platelet Responsiveness and In Vivo Thrombosis Potential

Demonstration of a direct effect of TMAO on platelet function suggests that gut microbiota and specific dietary nutrients that enhance TMAO generation should similarly modulate platelet function and thrombosis potential in vivo. To explore this possibility, mice were placed on a chemically defined diet comparable to normal chow (0.08% total choline) versus the same chemically defined diet supplemented with either TMAO (0.12%) or choline (1%). In addition, the effect of gut microbial suppression with a cocktail of oral broad-spectrum, poorly absorbed antibiotics (ABS) (Wang et al., 2011) was examined with both diets (Figure 3).

After 6 weeks, platelet-rich plasma was isolated from mice, platelet responsiveness to ADP stimulation was determined using ex vivo platelet aggregometry, and TMAO levels were quantified. Figure 3A shows a representative tracing from the platelet aggregometry studies of a mouse from each dietary group using 1 μM ADP as agonist, while data in Figure 3B represent scatter-plots and cumulative statistical analyses of percent maximal aggregation results at the sub-maximal ADP dose as an agonist for each of the dietary ± ABS groups of mice. Examination of plasma TMAO revealed elevated levels in mice provided dietary supplementation with either choline or TMAO. In parallel, ex vivo platelet aggregation induced by ADP stimulation was significantly increased in these groups (Figure 3B). Moreover, the enhancing effect of dietary choline on platelet aggregation was suppressed in mice receiving oral ABS, which markedly reduces plasma TMAO levels (Figures 3A and 3B). Importantly, provision of ABS to the TMAO supplemented group did not have a significant effect on either plasma TMAO levels or platelet aggregation (Figure 3B). Figure 3C illustrates parallel independent studies examining platelet activation in response to different concentrations of ADP or different agonists (collagen or arachidonic acid). Notably, TMAO supplementation similarly enhanced ex vivo platelet aggregometry responses to sub-maximal levels of each of the agonists examined (Figure 3C).

In further studies the impact of dietary choline, TMAO, and gut microbiota on in vivo thrombosis potential was examined using the carotid artery FeCl3 injury model using an overall study design identical to that used for the ex vivo platelet aggregometry studies above (Figure 3D). Consistently, in vivo thrombosis potential, as monitored by time to blood flow cessation in the carotid artery following FeCl3 injury, was shortened (indicating a more pro-thrombotic phenotype) in mice with heightened TMAO levels (choline or TMAO supplemented diet groups) (Figure 3D). Importantly, the effect of dietary choline on in vivo thrombosis was inhibited by concurrent oral ABS administration, which suppresses the gut microbiota and TMAO levels.
We also examined the impact of each dietary intervention on platelet counts, along with other metabolic parameters (Table S1), and saw no differences to account for the observed effects on in vivo thrombosis potential. In a complementary set of studies, we employed photochemical injury using rose bengal as a photosensitizing agent as an alternative trigger of platelet activation and thrombosis in vivo (Figure 3E) (Furie and Furie, 2008). Mice were placed on the chemically defined chow diet (0.08% total choline) versus the same diet supplemented with either TMAO (0.12%) or choline (1%) for 1 week, at which point rose bengal was injected, the mid portion of the common carotid artery was illuminated with a 1.5 mW green light laser, and blood flow was continuously monitored by doppler, as described in the Experimental Procedures. Notably, dietary TMAO or choline supplementation each markedly increased plasma TMAO levels and was accompanied by significant shortening of occlusion time (Figure 3E).

Next, we sought to determine whether the enhancing effect of dietary choline supplementation on platelet function was due to a factor(s) that was contained within platelet-poor plasma, as anticipated for TMAO, or whether the platelets themselves showed altered responsiveness when recovered from mice chronically on the choline supplemented diet. Platelet-rich plasma from each group of mice was recovered and then further fractionated into a washed platelet versus platelet-poor plasma fraction under ultracentrifugation conditions that also removed microparticles and exosomes, as described in the Experimental Procedures. As shown in Figure 3F, enhanced platelet aggregation responses in add-back/mixing studies revealed that the hyperresponsive phenotype followed the choline diet-derived platelet-poor plasma. In contrast, the source of the washed platelets (chow versus choline diet fed animals) failed to impact the overall extent of platelet aggregation monitored.
in vivo thrombosis studies (FeCl₃-induced carotid artery injury model) using germ-free C57BL/6J mice housed under sterile conditions, their conventional (microbe-colonized) counterparts, or germ-free mice after conventionalization (housing in conventional cages to permit microbe colonization). All mice were maintained on the indicated diets for 6 weeks, and plasma was recovered for TMAO analyses on the day of the in vivo thrombosis assay. As previously observed, conventional mice supplemented with either dietary choline or TMAO (relative to the control (chow) group) showed significant increases in plasma TMAO levels, and in parallel, enhanced thrombosis (reductions in carotid artery time to cessation of blood flow following FeCl₃ injury; Figure 4A). In contrast, within the germ-free mice, supplementation with choline no longer produced TMA (and hence TMAO) or the pro-thrombotic phenotype. Moreover, provision of dietary TMAO within the germ-free mice (bypassing the need for gut microbes to elevate TMAO) resulted in significant shortening in the time to cessation of blood flow (Figure 4A).

Specific Gut Microbial Taxa Associated with Both TMAO Levels and Thrombosis Potential
To identify microbial genera associated with dietary choline-induced enhancement in plasma TMAO levels and accompanying pro-thrombotic phenotype compared with chow-fed conventionalized mice (Figure 4A). Examination of the relationship between plasma TMAO levels and a quantitative measure of thrombosis potential (time to cessation of blood flow using the carotid artery injury model) across all groups of mice studied revealed a significant negative correlation (R = -0.62; p < 0.001; Figure 4B).
to visualize whether community differences were observed between cecal microbes in mice on the chow versus choline-supplemented diets. Distinct (non-overlapping) clusters were observed (Figure 4C; p < 0.001 for Student’s t test with 1,000 Monte Carlo simulations), suggesting chronic exposure to supplemental dietary choline induced a significant rearrangement in the overall cecal microbial composition. Linear discriminant analysis (LDA) coupled with effect size measurements (LEfSe) further identified cecal microbial taxa that accounted for the greatest differences observed in mice on the distinct diets. In total, eight taxa were identified through LEfSe analyses as being characteristic of choline versus chow diet (Figure 4D), where choline diet significantly increased proportions of three genera (Figures S3A–S3C) and decreased five genera (Figures S3D–S3H).

In further analyses of the detected cecal genera within all groups of mice, nine taxa were identified whose proportions were significantly associated with plasma TMAO levels (FDR adjusted p < 0.1), and 15 taxa were identified whose proportions were significantly associated with in vivo thrombosis potential (i.e., occlusion time; FDR adjusted p < 0.1) (Figure S4A; Table S2). The proportions of eight taxa were significantly associated with both plasma TMAO levels and occlusion time, and in every case, microbial taxa positively associated with higher plasma TMAO levels were associated with shorter time to blood flow cessation (more pro-thrombotic), whereas taxa significantly associated with reduced TMAO levels were associated with longer time to blood flow cessation (Figure 4A; Table S2). Interestingly, the proportions of most of the identified bacterial taxa characteristic of a high choline diet were also positively associated with a pro-thrombotic phenotype (shorter occlusion time). For example, the proportion of Allobaculum, a high choline diet characteristic taxa, was significantly positively associated with TMAO levels and shortened internal carotid artery occlusion times (Figure 4E, left; Figure S4). In contrast, alternative bacterial taxa that showed significant reduction in proportion, such as Candidatus Arthromitus or Lachnospiraceae, were associated with both lower TMAO levels and an anti-thrombotic phenotype (longer occlusion times) (Figure 4E, right; Figure S4).

Metagenomic analyses were also performed following shotgun sequencing of the cecal microbiota within mice from each of the three diets. Over 6,000 species and strains were detected altogether. Table S3 lists the KEGG pathways that were present, indicating those that were identified in one or more samples and the significance of differences in abundance between the diets, and Figure S5 summarizes microbial pathways significantly different between cecal microbes recovered from the different dietary groups of mice. In addition to the choline utilization gene cluster identified in Desulfovibrio desulfuricans (Craciun and Balskus, 2012), several human gut microbiota reference species associated with TMA production, encoding the CutC/CutD, YeaW/X and CntA/B enzymes recently identified (Falony et al., 2015; Koeth et al., 2014), were also observed. Table S4 lists all of those detected in one or more samples in our study, as well as differences in abundance between the diets. In recent studies Romano et al. (2015) examined 79 common gut microbes isolates and tested these in vitro for choline consumption and TMA production. Of these, eight were found to be TMA producers, and all eight were present in the metagenomic data from the mice in our study: Anaerococcus hydrogenalis, Clostridium asparagus, Clostridium hathewayi, Clostridium sporogenes, Escherichia fergusonii, Proteus penneri, Providencia rettgeri, and Edwardsiella tarda. Of these, only the first three differed significantly between the chow and choline diets; however, surprisingly, these tended to be more abundant in mice from the chow versus high choline diet groups (Table S4). These results underscore the complex community dynamic operating in vivo is more relevant to global TMA/TMAO production, as opposed to the in vitro ability of an individual microbial species to produce TMA from choline. Moreover, additional microbial TMA lyases no doubt exist that can contribute to TMA/TMAO production besides those already reported.

**Cecal Microbial Transplantation Studies Demonstrate Thrombosis Potential Is a Transmissible Trait**

Next, we sought to test whether the effect of dietary choline on thrombosis potential is transmissible with microbial transplantation (i.e., fulfillment of an essential Koch’s [1880] postulate). We recently examined TMAO levels in a mouse diversity panel comprised of over 20 different inbred strains of mice and identified C57BL/6J as a “high TMAO”-producing atherosclerotic disease-prone strain and NZW/LacJ as a “low TMAO”-producing disease-resistant strain (Gregory et al., 2015). In addition, we successfully used cecal contents from these inbred strains of mice as donors of functionally distinct stable microbial communities in transplantation studies, revealing that both atherosclerosis susceptibility and TMA/TMAO production are transmissible traits (Gregory et al., 2015). Before further using these inbred strains as donors in cecal microbial transplantation studies exploring thrombosis potential, we thought it important to first confirm that the high TMAO-producing strain (C57BL/6J) showed shorter occlusion time (more pro-thrombotic phenotype) than the low TMAO-producing strain (NZW/LacJ), particularly on a high choline diet. Conventional C57BL/6J and NZW/LacJ mice were maintained for 6 weeks on chemically defined chow (0.08% total choline) versus choline supplemented (1.0% total choline) diets. On the day of in vivo thrombosis assay, plasma TMAO levels in the C57BL/6J mice were over twice as high as those observed in the NZW/LacJ mice on the corresponding diet in both normal chow and choline-supplemented diets of the study (Figure S6A). Interestingly, whereas a choline-supplemented diet fed to C57BL/6J mice provoked a significant pro-thrombotic phenotype (p = 0.0002 relative to chow), the NZW/LacJ mice on the choline-supplemented (versus chow) diet exhibited only a trend (p = 0.07) toward reduced carotid artery occlusion time following FeCl3-induced injury (Figure S6A).

Based on the above results, we proceeded with cecal microbial transplantation studies using C57BL/6J (“high TMAO,” “pro-thrombotic”) and NZW/LacJ (“low TMAO,” “low thrombotic”) mice as cecal microbial donor strains and germ-free mice (C57BL/6J) as recipients. For 6 weeks preceding the start of the study, all mice (both donors and germ-free recipients) were maintained on the chemically defined (sterile) chow diet. Following cecal microbial transplantation, recipients were individually housed in separate microisolators and maintained on...
sterile (irradiated) chow versus choline-supplemented diets, as described in the Experimental Procedures (overall scheme is shown in Figure 5A). Successful transplantation of differential microbial choline TMA lyase enzyme activity in the donors (measured by conversion of d9-choline into d9-TMA in cecum) was observed in the recipients following transplantation (Figure 5B). In contrast, examination of hepatic FMO enzyme activity, which is responsible for converting TMA into TMAO (Wang et al., 2011; Bennett et al., 2013), revealed no significant differences between both donor mouse strains and among the various recipient groups post-cecal microbial transplantation (Figure S6B). Results of plasma TMAO levels on the day of sacrifice, platelet function (ex vivo platelet aggregometry), and in vivo thrombosis potential (FeCl3 carotid artery injury model) in each group of mice are shown in Figures 5C and 5D. First, as previously observed, germ-free recipients following microbial transplantation with C57BL/6J cecal contents showed a significant ~2-fold increase in plasma TMAO levels compared to recipients on the comparable diets receiving microbial transplantation with NZW/LacJ cecal contents (Figures 5C and 5D). Moreover, recipient mice following microbial transplantation with C57BL/6J cecal contents on the choline supplemented diet showed ~10-fold increase in plasma TMAO level and accompanying enhanced platelet responsiveness to sub-maximal ADP dose during platelet aggregometry studies compared with chow-fed controls (p < 0.001; Figure 5C). Similarly, recipients of the C57BL/6J cecal microbes maintained on the choline-supplemented diet also showed significant shortening of time to blood flow cessation during in vivo thrombosis assay (p < 0.001; Figure 5D). In contrast, a blunted (relative to C57BL/6J) rise in TMAO in the recipients receiving NZW/LacJ cecal microbes and placed on choline-supplemented diet was observed, with a correspondingly reduced effect of choline diet on both platelet responsiveness and in vivo thrombosis potential (Figures 5C and 5D).

Transplanted Cecal Microbial Taxa Associate with TMAO Levels and Thrombosis Potential
Cecal microbial composition in donors (on chow diet) and germ-free recipients post transplantation on the distinct diets (chow versus choline supplemented) was examined as before by
sequencing microbial DNA encoding 16S ribosomal RNA and performing principal coordinates analyses. Clear differences in community structure were visualized between cecal microbes recovered from the donors (Figure 6A). Further, following transplantation, recipients of C57BL/6J cecal microbes showed cecal microbial composition similar to the C57BL/6J donors, and recipients of NZW/LacJ cecal microbes showed cecal microbial composition similar to the NZW/LacJ donors (Figure 6A). In addition, exposure to the high choline diet induced a shift in community composition within each recipient group, but the differences between (and similarities with their respective donor) the microbial community compositions in the respective recipients remained visible (Figure 6A).

In further studies we examined whether the proportions of any cecal taxa in recipient mice from the above microbial transplantation study were significantly correlated with either plasma TMAO levels or in vivo thrombosis potential (occlusion time) at time of sacrifice (Figure S7). Of note, the proportions of several taxa previously identified in analyses of mice on chow versus choline-supplemented diets as being associated with TMAO levels and in vivo thrombosis potential (Figures 4E and S4; Table S2) were again observed to be significantly associated with TMAO levels and occlusion time. Specifically, proportions of three taxa in recipient cecal microbes were identified when grouped by dietary treatment as again being significantly associated with both plasma TMAO levels and occlusion time. Genus *Prevotella* and order *YS2* from the *Cyanobacteria* phylum are examples of *C57BL/6J* donor characteristic taxa identified by the LEfSe analyses that in recipients were positively associated (after FDR correction) with plasma TMAO levels and negatively with occlusion time (i.e., associated with a more “pro-thrombotic” phenotype).

**Figure 6. Characterization of Donor Characteristic Cecal Microbiota Associated with TMAO and In Vivo Thrombosis Potential in Recipients Following Microbial Transplantation**

(A) Intestinal microbial community composition was assessed by principal coordinates analysis for donor and recipient mouse strains on the indicated diets.

(B) Linear discriminant analysis (LDA) effect size (LEfSe) analyses were performed to identify taxa most characteristic (increased abundance) in NZW/LacJ and C57BL/6J donors.

(C) Illustration of three taxa identified in recipient cecal microbes whose proportions are significantly associated with both plasma TMAO levels and occlusion time when grouped by dietary treatment (blue squares, recipients of NZW/LacJ donor cecal microbes; red circles, recipients of C57BL/6J microbes). Values in both x and y directions are plotted as mean ± SE. Significance was determined using unpaired Student’s t test.

See also Figure S7 and Table S5.
adjustment) with TMAO and negatively with time to occlusive clot formation (Figures 6C and 6D). In similar analyses, of the 14 taxa identified as being characteristic of the NZW/LacJ donors in LEfSe analyses (Figure 6B; taxa depicted in blue), when examined in recipient cecal microbes, the proportions of eight taxa either trended or were significantly negatively associated with TMAO levels and positively associated with time to cessation of flow (i.e., less thrombotic phenotype). The genus Peptococcaceae is an example of a taxa identified as being characteristic of the NZW/LacJ donors and that was observed to be both significantly negatively associated with TMAO levels and positively associated with in vivo time to occlusive clot formation within recipients (Figure 6E).

DISCUSSION

The present studies reveal the interesting finding that gut microbes modulate thrombosis potential in vivo. They also expand our understanding of the relationship between TMAO and CVD risk. The TMAO meta-organismal pathway has been shown to possess numerous clinical and mechanistic links (Figure 7A) with both atherosclerotic plaque development and whole-body cholesterol and sterol metabolism (Wang et al., 2011; Koeth et al., 2013, 2014; Gregory et al., 2015; Miao et al., 2015; Shih et al., 2015; Warrier et al., 2015). Moreover, circulating levels of TMAO have been shown in multiple distinct clinical studies and cohorts to be associated with CVD risks (Wang et al., 2011, 2014a; Tang et al., 2013, 2015; Lever et al., 2014; Troseid et al., 2015), and targeted suppression of microbial TMA/TMAO production has recently been shown to inhibit diet-induced atherosclerosis (Wang et al., 2015). The present studies expand on these findings and show that gut microbes, via generation of TMAO, can directly modulate platelet hyperresponsiveness and clot formation rate in vivo. A scheme illustrating the overall involvement of gut microbes and the TMAO meta-organismal pathway in platelet hyperresponsiveness and in vivo thrombosis potential, a critical determinant of patient vulnerability for adverse cardiac event risk, is illustrated in Figure 7A. Also shown are known effects of the gut microbial TMAO pathway on CVD, including the recent demonstration of adverse ventricular remodeling and heart failure risk (Organ et al., 2015) and arterial endothelial cell activation in vivo (Seldin et al., 2016). The influence of gut microbes on thrombosis risk via TMAO production requires the presence of an appropriate dietary input capable of producing TMA (e.g., foods rich in choline or phosphatidylcholine), the precursor for TMAO generation. Further, an obligatory role of gut microbes in choline diet-enhanced thrombosis was confirmed both in studies using germ-free mice and in conventional mouse studies in the presence versus absence of oral poorly absorbed broad spectrum antibiotics. Cecal microbial transplantation studies confirm that both choline diet-enhanced platelet responsiveness and in vivo thrombosis potential are transmissible traits. Finally, the results of large-scale human clinical studies with over 4,000 subjects underscore the potential clinical significance of the pathway, since elevated TMAO levels are independently associated with incident risk for thrombotic events (myocardial infarction or stroke) in subjects, even following adjustments for multiple risk factors, medication use, and CVD status.

The mechanisms through which dietary choline influences platelet responsiveness and function, impacting overall in vivo thrombosis risk, are illustrated in Figure 7B. First, a diet rich in choline alters microbial composition and function. Specifically, with choline supplementation, total cecal microbial choline TMA lyase activity was shown to increase, with parallel increases in both plasma TMAO levels and proportions of specific taxa associated with TMAO. The present studies also show that the effect of TMAO on platelet hyperresponsiveness is not stimulus specific; rather, multiple distinct agonists, including ADP, thrombin, collagen, and arachidonic acid, all showed TMAO-dependent enhancement in Ca^{2+} release from platelet intracellular stores and activation in the setting of sub-maximal agonist stimulation (Figure 7B). In addition, studies examining the effect of TMAO on IP_3 generation in platelets, a second messenger signaling molecule produced by various phospholipase C isoforms that triggers intracellular Ca^{2+} release leading to platelet activation, similarly showed TMAO-dependent enhancement. These observations collectively suggest the site of TMAO action in platelets is at a molecular level at, or proximal to, this step. Importantly, the effect of TMAO on platelet function was also dose dependent across the physiological range of TMAO concentrations observed in both humans and in animal models. Finally, the effect of TMAO on platelet reactivity and in vivo thrombosis was observed to be both rapid and reversible.

Despite the numerous findings and mechanistic insights revealed regarding the impact of TMAO on platelet function, the “chemical sensor” for TMAO within platelets remains unknown. Indeed, a receptor for TMAO in eukaryotic cells has not yet been reported. In contrast, TMA is a well-known ligand for an olfactory G protein-coupled receptor, trace amine-associated receptor 5 (TAAR5), which is specific for TMA and dimethylamine, but reportedly does not recognize either TMAO or numerous alternative methylamines (Wallrabenstein et al., 2013). Since orally ingested TMAO can in part be converted back to TMA by gut microbes, one might speculate that TMA, and thus TAAR5, might participate in the observed platelet phenotype. However, results of platelet aggregometry studies with direct addition of chemically pure TMAO, as well as studies employing germ-free mice and dietary TMAO supplementation, both strongly indicate that it is TMAO itself, and not TMA, that mediates the observed platelet hyperresponsiveness ex vivo and the pro-thrombotic phenotype in vivo. Whether there is a dedicated receptor on the platelets for TMAO or TMAO instead acts as an allosteric modulator of existing signaling pathways is unknown. TMAO is known to function as a small-molecule chaperone mimic, influencing protein conformation and function. Studies with isotope-labeled TMAO reveal it can enter cells (data not shown), but its site of action in modulating platelet function is at present unknown. Biophysically, TMAO is rather unique and possesses both hydrophobic and hydrophilic properties and the known ability to alter protein confirmation and stability (Brown et al., 1997; Singh et al., 2007). Discovery of the molecular receptor(s) that senses TMAO within cells like platelets is an area of intense interest.

In summary, the present work reveals the clinically relevant discovery that gut microbes, via generation of TMAO, participate in modulating platelet function and generation of a pro-thrombotic phenotype in vivo. The results thus suggest new potential
Figure 7. Summary Schemes Illustrating Gut Microbial Involvement in Development of Platelet Hyperresponsiveness and Atherothrombotic Heart Disease

(A) Global schema illustrating metaorganismal pathway linking dietary sources of choline abundant in a western diet, gut microbiota and host hepatic FMOs, resultant TMAO production, and subsequent development of hyperresponsive platelet phenotype and enhanced thrombotic event risk. The pro atherosclerotic effects of TMAO and the potential involvement of TMAO in development of vulnerable plaque are also shown. EC, endothelial cell; FMOs, flavin monooxygenases; Mφ, macrophage; TMA, trimethylamine; TMAO trimethylamine N oxide.

(legend continued on next page)
therapeutic targets and refinement of nutritional interventions for the prevention of adverse cardiovascular event risk. It is remarkable that numerous large-scale epidemiological studies have noted a relationship between a western diet, which is enriched in known nutrient TMAO precursors (e.g., choline, phosphatidylcholine, and camitine), and an enhanced risk for myocardial infarction, stroke, and death (Iqbal et al., 2008; Rohrmann et al., 2013). It also is relevant that anti-platelet agents are a cornerstone of current pharmacological interventions for the treatment and prevention of acute complications of CVD. These interventions are, however, hampered by their potential for bleeding as a complication (Jennings, 2009). The present studies suggest that targeting the gut microbial TMAO pathway as a treatment strategy, whether it be via dietary manipulation, alteration in microbial community with a probiotic or prebiotic, or direct pharmacological inhibition of microbial enzymes involved in TMAO production, has the potential to temper platelet hyperresponsiveness associated with elevated TMAO. Moreover, such pharmacological interventions would, in contrast to existing anti-platelet agents, be expected to reduce platelet hyperresponsiveness to normal range, and not induce impairment in overall platelet function. Thus, one could speculate that targeting this microbial pathway would foster a beneficial “anti-platelet” effect, attenuating pro-thrombotic tendencies, but without enhanced bleeding complications as a consequence. Studies into this possibility represent an attractive future area of investigation. Further examination of the clinical utility of TMAO levels as an indication of subjects who may benefit from anti-platelet prophylaxis therapy with low-dose aspirin or other platelet-directed antithrombotic drugs is also an area of considerable interest.

EXPERIMENTAL PROCEDURES

More complete experimental procedures are provided in the Supplemental Experimental Procedures.

General Procedures and Reagents

Reagents were purchased from Sigma unless otherwise stated. Protein concentration was determined by bicinchoninic acid (BCA) assay (Bio Rad). Hepatic FMO activity was quantified as described previously (Bennett et al., 2013). Mouse plasma total cholesterol and triglycerides were measured using Abbott ARCHITECT platform model ci8200 (Abbott Diagnostics).

Ethical Considerations

All animal model studies were approved by the Institutional Animal Care and Use Committee at the Cleveland Clinic. All study protocols and informed consent for human subjects were approved by the Cleveland Clinic Institutional Review Board. Informed consents were obtained from all subjects.

Mass Spectrometry Quantification of Plasma and Dietary Analytes

Stable isotope dilution liquid chromatography tandem mass spectrometry (LC MS/MS) was used for quantification of plasma TMA and TMAO, as well as the content of free and total choline of all chemically defined diets, as previously described (Wang et al., 2011, 2014).

Human Studies

The association between TMAO levels and incident thrombotic event risk was examined in the GeneBank Study (Tang et al., 2013). Platelets from consenting healthy volunteers were drawn into citrate tubes. Donors were pre-screened and confirmed to have fasting TMAO < 2.5 μM the day of blood draw. Platelet rich plasma, isolated human platelets, and aggregometry studies were performed as described in the Supplemental Experimental Procedures. Thrombosis studies in whole blood at physiological levels of shear stress were performed using the Cellix Microfluidics System (Cellix) with computer image assisted quantification of adherent platelets as described in the Supplemental Experimental Procedures. Inositol phosphate levels were quantified using the IP One ELISA Kit (Cisbio Bioassays) in accordance with the manufacturer’s instruction.

In Vivo Carotid Artery Thrombosis Models

Two in vivo thrombosis models were used. Mice were typically placed for 6 weeks on the indicated chemically defined diets (± oral broad spectrum antibiotics provided in the drinking water, where indicated) as previously described (Wang et al., 2011). For most studies, mice were subjected to common carotid artery injury by application of 10% FeCl3 for 1 min (Chen et al., 2008). In alternative studies, a photochemical carotid artery injury model was used as described in the Supplemental Experimental Procedures. In some experiments, plasma TMAO was acutely elevated by intraperitoneal injection (100 μl) of sterile stock solution (290 mM final in sterile water, pH adjusted to 7.4 using 0.1 N HCl) or sterile normal saline, and the carotid artery thrombosis model was performed 2 hr later.

Intracellular Ca2+ Measurements

Ratiometric fluorescence measurements were conducted with 8 × 105 washed human platelets resuspended in Hank’s buffered salt solution supplemented with bovine serum albumin and glucose and after incubation with Fura 2 AM (1 μM) and removal of unabsorbed FURA 2 AM. Changes in [Ca2+]i were monitored by measuring Fura 2 AM fluorescence using 340/380 nm dual wavelength excitation and an emission of 510 nm, as described in the Supplemental Experimental Procedures.

Germ-free Mouse Studies

Germ free C57BL/6J female mice bred and housed at the National Gnotobiotic Rodent Resource Center, University of North Carolina (UNC) were used in various studies. Mice were exposed to 3 weeks of the indicated chemically defined sterile diets as described in the Supplemental Experimental Procedures. Conventionalization of germ free mice and microbial transplantation studies were performed as described in the Supplemental Experimental Procedures.

Microbiota Studies

Cecal microbial community composition was assessed by sequencing 16S rRNA gene amplicons (Gregory et al., 2019), and metagenomic analyses were performed as described in the Supplemental Experimental Procedures, following shotgun sequencing of cecal microbes. Metagenomic data are deposited in MG RAST Argonne National Laboratory (http://metagenomics.anl.gov/) and can be accessed through project name: Platelet function and TMAO.

Statistical Analysis

Detailed statistical methods are described in the Supplemental Experimental Procedures. All studies were repeated at least three independent times with the number of biological replicates (animal groups) for a given experiment shown. Kaplan Meier survival plots and Cox proportional hazards analysis were used to determine Hazard ratio (HR) and 95% confidence intervals (95% CI) for thrombotic event (MI and stroke) risk stratified according to TMAO quartiles. Adjustments were made for individual traditional risk factors.
including age, sex, SBP, LDL, HDL, triglycerides, smoking, diabetes, esti-
mated creatinine clearance, medications, and CVD status. All data were
analyzed using R (v.3.1.0) and JMP (SAS Institute). For all statistical tests,
p < 0.05 was considered significant.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2016.02.011.

AUTHOR CONTRIBUTIONS

W.Z. participated in the design, performance, and analysis of most studies and
the drafting of the manuscript. J.C.G. participated in the design and perfor-
mance of microbial transplantation studies and analysis, human platelet
related studies, and the drafting of the manuscript. J.A.B. assisted in all mouse
studies, and N.G. helped with both microfluidic device studies and human platelet
related studies. Z.W. and X.F. performed all mass spectrometry ana-
yses. L.L. and Y.W. assisted with statistical analyses. R.B.S. supervised some of the
germ free mice experiments. E.O., M.M., and A.J.L. performed gut mi-
provided input on the experimental design and took part in thoughtful discus-
sions. S.L.H. conceived of the project idea and participated in the design of
experiments, data analysis, and the drafting of the manuscript. All authors crit-
ically reviewed and edited the manuscript.

ACKNOWLEDGMENTS

We thank Daniel I. Simon and Yunmei Wang (Case Western Reserve Univer-
sity) for technical assistance on the photochromic thombosis model. We thank Sorel Fitz Gibbon (UCLA) for assistance with metagenomic sequencing
data. This research was supported by grants from the NIH and the Office of
Dietary Supplements (P01HL103966, P20HL113452, HL29481, HL30568, 
R01DK106000, R01 HL122283, P40 OD010995, and P30 DK034987). Gene
Bank was supported by NIH grants (P01HL076491, P01HL098055, 
R01HL103931 and UL1TR 000439). W.Z. and Z.W. were supported in part
by AHA Scientist Development Grants. E.O. was supported by an FP7 grant
(no. 330381). S.L.H. was partially supported by the Leonard Krieger endow-
ment. Mass spectrometry instruments used were supported in part by AB
SCIEX. Z.W. and S.L.H. are named as co inventors on pending patents held
by the Cleveland Clinic relating to cardiovascular diagnostics or therapeutics.
Z.W. and S.L.H. report having the right to receive royalty payment for inven-
tions or discoveries related to cardiovascular diagnostics from Cleveland
Heart Lab, Inc. S.L.H. also reports having the right to receive royalty payments
for inventions or discoveries related to cardiovascular diagnostics or therapeu-
tsics from Siemens, Esperion, and Frantz Biomarkers, LLC. S.L.H. reports hav-
ing been paid as a consultant for Esperion and P&G and receiving research
funds from Astra Zeneca, P&G, Pfizer Inc., Roche Diagnostics, and Takeda.

Received: July 17, 2015
Revised: December 17, 2015
Accepted: February 8, 2016
Published: March 10, 2016

REFERENCES

Bäckhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., Semenko
vich, C.F., and Gordon, J.I. (2004). The gut microbiota as an environmental fac-
Bennett, B.J., de Aguiar Vallim, T.Q., Wang, Z., Shih, D.M., Meng, Y., Gregory,
N oxide, a metabolite associated with atherosclerosis, exhibits complex ge-
etic and dietary regulation. Cell Metab. 17, 49 60.
Brown, C.R., Hong Brown, L.Q., and Welch, W.J. (1997). Correcting tempera-
dependent signaling pathway is required for platelet activation by oxidized
low density lipoprotein. Circ. Res. 102, 1512 1519.
Cox, L.M., Yamanishi, S., Sohn, J., Alekseyenko, A.V., Leung, J.M., Cho, I.,
Kim, S.G., Li, H., Gao, Z., Mahana, D., et al. (2014). Altering the intestinal micro-
bacteria during a critical developmental window has lasting metabolic conse-
Craciun, S., and Balskus, E.P. (2012). Microbial conversion of choline to trime-
thylamine requires a glycol radical enzyme. Proc. Natl. Acad. Sci. USA 109,
21307 21312.
case of gut microbiota derived trimethylamine. Annu. Rev. Microbiol. 69,
305 321.
Frossard, M., Fuchs, I., Leitner, M., Hsieh, K., Veike, M., Losert, H., Domano
predicts myocardial damage in patients with acute myocardial infarction. Cir-
culation 110, 1392 1397.
J. Med. 359, 938 949.
sclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 290,
5647 5660.
Iqbal, R., Anand, S., Ounpuu, S., Islam, S., Zhang, X., Rangarajan, S., Chi
famba, J., Al Hina, A., Keita, M., and Yusuf, S.; INTERHEART Study Investi-
gators (2008). Dietary patterns and the risk of acute myocardial infarction in
gies to protect against platelet mediated atherothrombosis. Throm. Haem.
most. 102, 248 257.
Koch, R. (1880). Investigations into the Etiology of Traumatic Infective Dis-
esases (The New Sydenham Society).
trimethylamine N oxide as predictors of cardiovascular outcomes show different
Miao, J., Ling, A.V., Manthena, P.V., Gearing, M.E., Graham, M.J., Crooke,
R.M., Croce, K.J., Esquejo, R.M., Clish, C.B., Vicent, D., and Biddinger,
S.B.; Morbid Obesity Study Group (2015). Flavin containing monoxygenase
6, 6498.
Organ, C.L., Otsuka, H., Bhushan, S., Wang, Z., Bradley, J., Trivedi, R., Polhe
diet and its gut microbe derived metabolite, trimethylamine N oxide, exacer-
bate blood pressure overload induced heart failure. Circ. Heart Fail. 9, e002314.
Published online December 23, 2015.
Podrez, E.A., Byzova, T.V., Febbraio, M., Salomon, R.G., Ma, Y., Valliyaveetil,
links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 
13, 1086 1095.
Rev. Physiol. 52, 431 449.
Rohmann, S., Overvad, K., Bueno de Mesquita, H.B., Jakobsen, M.U., Ege
berg, R., Tjønneland, A., Nailer, L., Bouton Rusult, M.C., Clavel-Chapelon, F.,


